Below is a selection of institutions and programmes currently using the Ledidi Core platform to run local, national, and international registries and audits:
- University Hospitals of Leicester NHS Trust — clinical audit of breast cancer practice, initiated through the Pfizer oncology donation programme and since scaled into the pan-UK CONCISE Study across 21 NHS Trusts (Dr Olubukola Ayodele, Breast Cancer Lead). Read the case study
- Leeds Teaching Hospitals NHS Trust — Clinical Service Evaluation across multiple specialties, including three neurosurgery and brain tumour registries. Read the case study
- The Norwegian NeuroCovid Study
- The European Polyp Surveillance study (Spain, Norway, Netherlands, Sweden, Poland, Denmark, Austria, Portugal)
- Weill Cornell Medical College, New York, USA
The Pfizer donation will consist of two options:
Option 1 (Donation and Grant)
- Access to the Ledidi Core platform for 36 months
- The subscription will start once the healthcare professional (HCP)/Hospital Institution has created their account with Ledidi
- Ledidi offers personalised onboarding of the user, including data privacy support with Trust institution IT systems, within a reasonable scope
- Ledidi will ensure that they continue to provide support for the platform for the 36-month duration
- Pfizer will provide a one-off grant of £2,000 to help support the facilitation and data entry onto the Ledidi platform
Option 2 (Donation only)
- Access to the Ledidi Core platform for 36 months
- The subscription will start once the healthcare professional (HCP)/Hospital Institution has created their account with Ledidi
- Ledidi offers personalised onboarding of the user, including data privacy support with Trust institution IT systems, within a reasonable scope
- Ledidi will ensure that they continue to provide support for the platform for the 36-month duration
Hospital institutions utilising the Ledidi platform will retain ownership and control of any data that is uploaded: neither Pfizer nor Ledidi will be able to access or be privy to any data on the site. All patient level data held on the platform will be anonymised. Any sharing of data by the trust is through their own collaborations either within or outside of the platform and Ledidi is required to maintain adherence to data privacy laws. Currently, any hospitals within the UK treating the following patients are permitted to apply for this service donation grant:
- Acute Lymphoblastic Leukaemia (ALL)
- Breast cancer
- Lung cancer
- Multiple Myeloma
Forty subscriptions in total are available and hospitals will be selected to receive this donation on a first-come, first-served basis and based on the below criteria:
- Treating patients diagnosed with any of the cancers listed above
- At least one member of the hospital team dedicated to helping facilitate the audit including ensuring appropriate local data protection and IT facilitation
- Hospital institutions express intent to share best practice via local or national publication/congress presentation
All applications will be reviewed in order of application date and time on a first-come, first-served basis. Once all subscriptions have been allocated then the application portal will close. If a large number of applications are received all at once then the application portal may close until the backlog of applications is reviewed or until all grants are allocated, whichever occurs first.
All applications will be reviewed by an internal Pfizer medical review panel. Once you have submitted a request, we will also share further information regarding Ledidi Prime/Core. Additional clarification during the review period may be requested. All applicants will be notified via email regarding the outcome of their request, upon completion of the internal review process.
If your application is approved, your institution will be required to enter into a written grant agreement with Pfizer. In the event of a successful application, core terms of the agreement will be provided. Disclosure of this Pfizer donation will be required by each recipient hospital institution.
For further information on the data privacy and security of the Ledidi Real-World Evidence platform please refer to the following links.
Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. Pfizer accepts no responsibility for the content or services of the linked site.
All applications will be reviewed by an internal Pfizer medical review panel. Once you have submitted a request, we will also share further information regarding Ledidi Core. Additional clarification during the review period may be requested. All applicants will be notified via email regarding the outcome of their request, upon completion of the internal review process.
If your application is approved, your institution will be required to enter into a written grant agreement with Pfizer. In the event of a successful application, core terms of the agreement will be provided at a later date. Disclosure of this Pfizer donation will be required by each recipient hospital institution.